Hepatorenal protective and antitumor effects of astaxanthin-loaded chitosan nanoparticles against ehrlich ascites carcinoma in mice through antioxidant, anti-inflammatory, and apoptotic pathway modulation Authors: Mohammed Saleh Alfawaz, Ekramy M Elmorsy, Huda A Al Doghaither, Ayat B Al-Ghafari, Ahd A Mansour, Ahmad Najem Alshammari, Manal S Fawzy, Mona M Elghareeb Published: 2026 ABSTRACT AbstractBackgroundEhrlich ascites carcinoma (EAC) is an aggressive experimental tumor model associated with severe oxidative stress, inflammation, and hepatorenal injury. Astaxanthin (ASX), a potent natural antioxidant carotenoid, has demonstrated anticancer and cytoprotective properties; however, its therapeutic application is limited by poor bioavailability and stability. Therefore, this study investigated the anticancer and hepatorenal protective effects of astaxanthin-loaded chitosan nanoparticles (ASX-CNPs) compared with free ASX in EAC-bearing mice.MethodsNinety female Swiss albino mice were randomly allocated into six groups: control, ASX, ASX-CNPs, EAC, EAC + ASX, and EAC + ASX-CNPs. Tumor progression, survival rate, oxidative stress biomarkers, inflammatory mediators, apoptotic markers, and histopathological alterations in hepatic and renal tissues were evaluated. Antioxidant parameters included SOD, CAT, GPx, GSH, TAC, and TBARS. Inflammatory and apoptotic signaling pathways were assessed through measurement of COX-2, TNF-α, IFN-γ, IL-1β, Bcl-2, Bax, and caspase-3 expression levels.ResultsASX-CNPs markedly suppressed tumor progression and improved survival compared with free ASX. Treatment with ASX-CNPs significantly downregulated Bcl-2 expression while upregulating Bax and caspase-3, indicating enhanced apoptotic activity. Antioxidant defenses were significantly restored, as evidenced by increased SOD, CAT, GPx, GSH, and TAC levels, alongside reduced TBARS. Inflammatory responses were attenuated through decreased COX-2 activity and reduced TNF-α, IFN-γ, and IL-1β levels. Histopathological examination confirmed substantial protection against EAC-induced hepatic and renal damage. Overall, ASX-CNPs demonstrated greater therapeutic efficacy than free ASX across biochemical, molecular, and histopathological assessments.ConclusionsASX-loaded chitosan nanoparticles exerted potent anticancer, antioxidant, anti-inflammatory, and hepatorenal protective effects in EAC-bearing mice. The enhanced efficacy of ASX-CNPs relative to free ASX is likely attributable to improved bioavailability and targeted modulation of oxidative stress, inflammatory, and apoptotic pathways, supporting their potential as a promising nanotherapeutic strategy for cancer-associated organ injury.Graphical abstract Astaxanthin-loaded chitosan nanoparticles (ASX-CNPs) were developed to enhance the efficacy of astaxanthin against Ehrlich ascites carcinoma (EAC). Treatment with ASX-CNPs significantly reduced tumor growth and enhanced liver and kidney function compared to free ASX. The nanoformulation elevated pro-apoptotic marker levels (Bax, Caspase-3) and reduced oxidative stress (normalizing GSH and TAC levels) and inflammation (decreasing COX-2, TNF-α, IFN-γ, and IL-1β levels). ASX-CNPs demonstrate significant anticancer and hepatorenal protective effects through the regulation of apoptotic, oxidative, and inflammatory signaling pathways. Keywords: Astaxanthin, Chitosan nanoparticles, Ehrlich ascites carcinoma, Antioxidant defense, Apoptosis, Inflammation Introduction Cancer continues to represent a major cause of death worldwide, despite remarkable progress in both therapeutic development and scientific understanding [1]. Oxidative stress contributes significantly to cancer development by promoting mutagenic alterations and causing cellular injury [2]. Cytokines in the tumor microenvironment act as key mediators of cancer progression, influencing tumor growth and metastasis through complex inflammatory and immune-regulatory mechanisms [3]. Ehrlich Ascites Carcinoma (EAC) is widely used as an experimental tumor model because of its undifferentiated nature, high malignancy, and rapid growth, making it ideal for investigating tumor biology and evaluating therapeutic interventions [2, 4]. Tumor development in this model is closely tied to oxidative stress, as elevated reactive oxygen species (ROS) levels induce tissue injury, tumor invasion, and DNA mutations [5, 6]. These insights have fueled interest in plant-derived compounds, which possess potent antioxidant, proapoptotic, and anticancer effects. Notably, approximately 60% of clinically approved anticancer agents are derived from medicinal plants, highlighting their critical role in the development of new cancer therapies [4, 7]. Natural products exhibiting pleiotropic biological activities have garnered significant interest as potential therapeutics for cancer and related organ damage due to their robust antioxidant, anti-inflammatory, antiapoptotic, and immunomodulatory properties [8]. Among these compounds, carotenoids and other naturally occurring bioactives have demonstrated considerable potential in enhancing redox homeostasis and mitigating cancer-associated tissue damage by modulating Nrf2/HO-1, NF-κB, and mitochondrial apoptotic pathways [9–11]. Astaxanthin (ASX) exhibits significant anticancer efficacy owing to its robust antioxidant properties and distinctive molecular structure [12]. It exerts its anticancer effects through multiple mechanisms, such as inhibiting malignant cell proliferation, blocking tumor initiation, and promoting apoptosis in cancerous tissues [13, 14] through several aberrant related signaling pathways [15]. Its dual function in suppressing oxidative DNA injury and regulating genes involved in apoptosis and cell cycle progression reinforces its chemopreventive and therapeutic actions [16, 17]. Additionally, ASX exhibits potent anti-inflammatory properties that contribute to its anticancer potential, primarily by inhibiting NF-κB and COX-2 signaling pathways [18, 19]. Previous experimental studies have demonstrated anticancer and cytoprotective effects of free ASX in several tumor models; however, the magnitude and consistency of its in vivo efficacy remain variable due to pharmacokinetic and formulation-related constraints [12, 20] Because of its broad spectrum of biological effects, it holds promise as a natural therapeutic capable of regulating the intricate pathways involved in cancer development and progression, supporting its role as a potential adjunct in anticancer treatment. Nevertheless, the clinical translation of ASX remains constrained by adverse effects, including gastrointestinal disturbances, diarrhea, and muscle pain [21], in addition to its inherently low aqueous solubility (< 2 µg/mL at pH 6.5) and limited chemical stability [22]. In addition to these limitations, ASX shares with other carotenoids a strong lipophilic nature that restricts its intestinal absorption, resulting in limited oral bioavailability (10–50%) due to inefficient uptake by intestinal epithelial cells and poor solubility [23, 24]. To address these pharmacokinetic and physicochemical challenges, several innovative drug delivery systems have been introduced. Among them, nanocarriers have emerged as promising platforms due to their high biocompatibility, ease of surface modification, and capacity for controlled release and targeted drug delivery [25]. In particular, chitosan-based nanoparticles (CNPs) have gained wide application in the delivery of bioactive compounds owing to their excellent physicochemical stability, non-toxicity, biocompatibility, targeted delivery capabilities, and enhanced bioavailability with proved enhanced therapeutic and anticancer effects [21, 26–29]. Recent studies have reported ASX nanoformulations with improved stability and bioavailability in selected cancer models [21, 30], but these investigations have largely focused on general antitumor activity without parallel evaluation of systemic organ protection or detailed apoptotic and inflammatory signaling in EAC. Importantly, direct in vivo comparisons between free ASX and ASX-loaded chitosan nanoparticles in the EAC model are scarce, and integrated assessment of antitumor efficacy together with hepatorenal protection and mechanistic biomarkers has not been adequately addressed. While numerous studies have focused on astaxanthin-loaded chitosan nanoparticles (ASX-CNPs), few in vivo studies have examined their therapeutic efficacy in the EAC model compared with crude ASX. Therefore, the specific knowledge gap lies in the lack of a comprehensive EAC-based evaluation linking nanoformulation-enhanced delivery of ASX with tumor suppression, apoptosis modulation, oxidative stress control, inflammatory signaling, and concurrent hepatic and renal protection. To the best of our knowledge, this study represents a comprehensive investigation of ASX-CNPs in the EAC model, evaluating both their pro-apoptotic effects on tumor cells and their protective roles in hepatic and renal tissues. This approach defines the novelty of the present work and clearly differentiates it from prior ASX and ASX–nanoparticle studies. Materials and methods Preparation and characterization of ASX-CNPs Astaxanthin (≥ 98% purity), purchased from AB Chem Company (Mansoura, Egypt), served as the active compound in the ASX-CNP formulation. A chitosan solution (2 mg/mL) was prepared in 1% acetic acid containing 1% Tween 80, and the mixture was subjected to ultrasonic treatment for 15 min to obtain a homogeneous solution. The pH was subsequently adjusted to 5 with 2 N NaOH to optimize nanoparticle formation. Astaxanthin (0–3000 µg/mL) was added to the chitosan mixture, which was then sonicated for 5 min to homogenize. The concentration range of astaxanthin (0–3000 µg/mL) was selected based on previously published studies and preliminary experiments aimed at optimizing nanoparticle formation and encapsulation efficiency. This range allowed us to evaluate the effect of increasing drug loading on nanoparticle characteristics, including size, polydispersity, and encapsulation performance, without compromising stability [31]. TPP solution, freshly prepared in deionized water, was subsequently introduced dropwise under constant stirring at a chitosan-to-TPP ratio of 5:1 (w/w) to induce ionic crosslinking. Magnetic stirring was continued for 1 h to ensure complete ionic crosslinking and stabilization of the chitosan–TPP network. The resulting nanoparticles were harvested by centrifugation at 12,000 × g for 20 min at 4 °C, followed by two washes with deionized water to remove residual ASX or unreacted TPP. The purified nanoparticles were then frozen at − 80 °C and lyophilized to obtain dry, stable ASX-CNPs. Nanoparticle size, polydispersity index (PDI), and zeta potential were analyzed using a Zetasizer Nano ZS (Malvern Instruments, UK). Samples were diluted with distilled water before measurement, and all analyses were performed in triplicate to calculate mean Z-average values. The morphology of the nanoparticles was examined using transmission electron microscopy (TEM) (JEOL 2100, Japan) operated at an accelerating voltage of 160 kV. Chitosan (Sigma-Aldrich, USA) with a molecular weight of 190–310 kDa and a degree of deacetylation of 85% was utilized, as these characteristics are known to affect nanoparticle stability and encapsulation efficiency. Encapsulation performance was determined by calculating the loading efficiency (LE) and loading content (LC) of ASX, representing the proportion of drug successfully entrapped within the nanoparticles. The ASX calibration curve was constructed from serial standard concentrations measured at 334 nm. After nanoparticle preparation, the concentration of free ASX in the supernatant was quantified using UV–Vis spectrophotometry. Encapsulation performance was evaluated in terms of LE and LC using the following formulas: LE (%) = [ASX encapsulated / ASX initially added] × 100; LC (%) = [ASX encapsulated / Total nanoparticle weight] × 100. FTIR spectroscopy was performed to confirm the successful encapsulation of ASX within the chitosan nanoparticle matrix and to detect possible chemical interactions between ASX, chitosan, and TPP. Spectra of pure ASX, pure chitosan, pure TPP, their physical mixture, and the prepared ASX-CNPs were recorded using an FTIR spectrophotometer (Nicolet iS10, Thermo Fisher Scientific, USA) in the wavelength range of 4000–400 cm⁻¹. Samples were finely ground and mixed with KBr powder, then compressed into translucent pellets prior to scanning. The FTIR spectrum of pure ASX exhibited characteristic absorption peaks at ~ 2920 cm⁻¹ and ~ 2850 cm⁻¹ corresponding to C–H stretching vibrations, a prominent peak near 1650 cm⁻¹ associated with C = O stretching, and bands around 1450–1370 cm⁻¹ related to C = C and C–O stretching of the polyene chain. Chitosan displayed distinctive peaks at ~ 3430 cm⁻¹ (O–H and N–H stretching), 1645 cm⁻¹ (amide I), and 1550 cm⁻¹ (amide II), while TPP showed absorption bands at ~ 1210 cm⁻¹ and 1130 cm⁻¹ due to P = O and P–O–P stretching vibrations, respectively. In the ASX-CNP spectrum, the disappearance or broadening of ASX-specific peaks and the shifting of chitosan amide bands toward lower wavenumbers indicated the formation of electrostatic and hydrogen-bonding interactions between the phosphate groups of TPP and the amino groups of chitosan, as well as possible hydrophobic interactions with ASX molecules. These spectral modifications confirmed the successful incorporation of ASX within the chitosan–TPP network rather than a mere physical mixture. The FTIR results, therefore, substantiated the presence of strong intermolecular interactions, responsible for enhanced nanoparticle stability and ASX-CNPs’ encapsulation efficiency. In vitro release study of ASX from chitosan nanoparticles The in vitro release profile of astaxanthin (ASX) from ASX-loaded chitosan nanoparticles (ASX-CNPs) was evaluated using the dialysis bag diffusion method to simulate physiological conditions. Briefly, an accurately weighed amount of lyophilized ASX-CNPs, equivalent to a known ASX content, was dispersed in 2 mL of release medium and transferred into a dialysis membrane (molecular weight cut-off: 12–14 kDa), which was securely sealed at both ends. The dialysis bags were immersed in 50 mL of release medium consisting of phosphate-buffered saline (PBS, pH 7.4) containing 0.5% (w/v) Tween 80 to maintain sink conditions and enhance ASX solubility. The system was maintained at 37 ± 0.5 °C with continuous gentle shaking at 100 rpm to mimic physiological conditions. At predetermined time intervals (0.5, 1, 2, 4, 6, 8, 12, 24, and 48 h), 2 mL of the release medium was withdrawn and immediately replaced with an equal volume of fresh pre-warmed PBS to maintain a constant volume. The collected samples were centrifuged if necessary to remove any particulate matter, and the amount of released ASX was quantified using UV–Vis spectrophotometry at 334 nm against a previously established calibration curve. All experiments were conducted in triplicate, and results were expressed as mean ± standard deviation (SD). The cumulative percentage of ASX released was calculated using the following equation: Cumulative ASX release (%) = To elucidate the release mechanism, the in vitro release data were fitted to various kinetic models, including zero-order, first-order, Higuchi, and Korsmeyer–Peppas models. The model with the highest correlation coefficient (R²) was considered to best describe the ASX release behavior from the chitosan nanoparticle system. Induction of EAC in mice The EAC parental cell line, acquired from the National Cancer Institute (NCI), Cairo, Egypt, was propagated in vivo by intraperitoneally injecting 2.5 × 10⁶ cells into female Swiss albino mice every 10 days [2]. Anesthesia was induced in mice by intraperitoneal administration of ketamine (80 mg/kg) and xylazine (10 mg/kg). Under this anesthesia, ascitic fluid was collected from EAC-bearing mice on the 7th or 8th day after tumor inoculation. Viable cell counts were performed on the ascitic fluid using a hemocytometer with 0.4% trypan blue [32], and the resulting cell suspension was adjusted to contain 2.5 × 10⁶ viable tumor cells in 0.2 mL of PBS for experimental use. Animal handling and experimental protocol A total of ninety female Swiss albino mice, each weighing around 20.8 g, were obtained from the MERC Center at the Faculty of Medicine, Mansoura University, Egypt. They were maintained in standard plastic cages under regulated conditions (25 °C, ~ 45% humidity, 12-hour light/dark cycle) with ad libitum access to food and water. Prior to initiating the experiment, animals were acclimated for one week. Experimental procedures followed the Guide for the Care and Use of Laboratory Animals (NRC, 2011, 8th edition) and conformed to the International Guiding Principles for Biomedical Research Involving Animals (1985). All experimental animals were randomly assigned to treatment groups using a computer-generated randomization schedule to ensure unbiased allocation. Mice were randomly allocated into six groups of 15 each: (1) untreated control (orally administered 0.2 mL saline solution), (2) ASX (40 mg/kg/day, orally), a dose selected based on previous in vivo studies demonstrating significant anticancer and organ-protective effects in murine tumor models [33]; preliminary pilot testing confirmed tolerability and measurable biological response, (3) ASX-loaded chitosan nanoparticles (ASX-CNPs) alone (40 mg/kg/day, orally), (4) EAC-bearing mice inoculated intraperitoneally with 2.5 × 10⁶ cells on day 1 and left untreated for 20 days and orally given 0.2 mL saline, (5) EAC + ASX (treated orally with ASX for 20 days following inoculation, based on the established dose and duration from pilot assessment), and (6) EAC + ASX-CNPs (treated orally with ASX-CNPs for 20 days following inoculation using the same dosing rationale). Body weights were measured at baseline and at the end of the study, while the survival of EAC-bearing mice was observed daily. Seven mice from each group were allocated for biochemical, histopathological, and molecular analyses. Any deaths in the EAC-bearing groups were recorded and included in survival assessments. Mean survival time (MST) was determined following BA Teicher and PA Andrews [34] by averaging the time of the first and last deaths using the formula: MST = (first death + last death) / 2. Accordingly, all experimental groups were evaluated over an identical 20-day period, with the untreated EAC group serving as the concurrent disease control, enabling direct comparison of treatment effects against matched tumor progression under the same experimental timeline. It is important to note that this experimental design primarily reflects a preventive/early intervention model rather than a delayed therapeutic setting against established tumors. Sample collection and biochemical analysis At the end of the experiment, seven mice from each group were sacrificed via deep isoflurane (5% in oxygen for 5 min) anesthesia. Death was confirmed by absent respiration and heat beats. To standardize blood collection, animals were fasted for 10 h and anesthetized with inhaled isoflurane to minimize stress, followed by euthanasia via isoflurane overdose (5% in oxygen for 5 min). Death was confirmed by cessation of respiration and heartbeat. Blood was collected via retro-orbital sinus puncture into plain tubes, and the resulting serum was preserved for later biochemical assays. Serum biochemical parameters were assessed using commercially available kits. These included total protein (TP; Cat. No. CBP007-K), albumin (Alb; Cat. No. MET-5017), alanine aminotransferase (ALT; Cat. No. MET-5123), aspartate aminotransferase (AST; Cat. No. MET-5127), lactate dehydrogenase (LDH; Cat. No. MET-5131), γ-glutamyl transferase (GGT; Cat. NK1120FY100.), and alkaline phosphatase (ALP; Cat. No. CBA-301), all obtained from Creative Biolabs, USA. Globulin (Glo) concentration was calculated by subtracting albumin from total protein. Serum urea (Cat. No. STA-382) and creatinine (Cat. No. STA-378) were measured using kits from Cell Biolabs, USA. Serum electrolyte levels—including potassium (K+), calcium (Ca++), sodium (Na+), and chloride (Cl−)—were determined using commercial kits (Sensa Core Electrolyte, India). All assays were performed according to the manufacturers’ protocols. Collection of ascitic fluid and quantification of viable tumor cells Tumor cell samples were diluted 1:100 in a 0.4% trypan blue solution in PBS. Viable cells were counted using a Neubauer hemocytometer, with 25 secondary squares evaluated for each sample. Non-viable cells were stained blue, whereas viable cells remained unstained, as described by CJ Walsh and CA Luer [35]. Counts from treated groups were compared with those from the untreated EAC group. Viable cell numbers were calculated using the following formula. Cell count = (Dilution factor × Number of cells) / (Thickness of the liquid film × Area). The abdominal circumference of EAC-bearing mice was measured using a flexible tape at the widest part of the abdomen above the umbilicus. Measurements were recorded in millimeters (mm). Analysis of mRNA expression RNA was isolated from tumor cells of EAC-bearing mice using 1 mL QIAzol Lysis Reagent and Tissuelyser II homogenization. After the addition of chloroform and centrifugation at 12,000 × g for 15 min, RNA was collected from the aqueous phase. The RNA pellet obtained after isopropanol precipitation was washed with ethanol and centrifuged at 7,500 × g for 5 min to remove any residual ethanol. Total RNA was resuspended in DNase/RNase-free water and its concentration determined. cDNA was synthesized using the iScript™ cDNA Synthesis Kit following the manufacturer’s protocol. The synthesized cDNA was subsequently used as a PCR template in combination with iTaq™ Universal SYBR® Green Supermix (Bio-Rad, Cat. No. 172–5121). Primers specific for each target gene were purchased from OriGene (Rockville, MD, USA) and are provided in Table 1. Primers were dissolved in nuclease-free water. qPCR was conducted using a Rotor-Gene Q system (Qiagen), and relative gene expression was analyzed via the 2^–ΔΔCt method [36]. Melt curve analysis confirmed primer specificity by showing a single peak, and β-Actin expression was stable across treatments, supporting its use as a reference gene. All reported fold-change values were rigorously normalized to β-actin, ensuring the validity of the relative gene expression results. Table 1Sequences of primers used in qRT-PCR analysisGeneSequences (5′-3′)Amplicon size (bp) Bax F: GTCTCCGGCGAATTGGAGATR: ACCCGGAAGAAGACCTCTCG100 BCL-2 F: CATCGCCCTGTGGATGACTR: GGCCATATAGTTCCACAAAGGC95 Caspase-3 F: GGAGTCTGACTGGAAAGCCGAAR: CTTCTGGCAAGCCATCTCCTCA170 β-Actin F: ACTATTGGCAACGAGCGGTTR: CAGGATTCCATACCCAAGAAGGA360Bax Bcl-2-associated X protein, BCL-2 B-cell lymphoma 2, Caspase-3 Cysteine-aspartic acid protease 3, β-Actin Beta-Actin (reference housekeeping protein) Sequences of primers used in qRT-PCR analysis F: GTCTCCGGCGAATTGGAGAT R: ACCCGGAAGAAGACCTCTCG F: CATCGCCCTGTGGATGACT R: GGCCATATAGTTCCACAAAGGC F: GGAGTCTGACTGGAAAGCCGAA R: CTTCTGGCAAGCCATCTCCTCA F: ACTATTGGCAACGAGCGGTT R: CAGGATTCCATACCCAAGAAGGA Bax Bcl-2-associated X protein, BCL-2 B-cell lymphoma 2, Caspase-3 Cysteine-aspartic acid protease 3, β-Actin Beta-Actin (reference housekeeping protein) Antioxidant status and inflammation Liver and kidney tissues were excised immediately after euthanasia, rinsed with ice-cold phosphate-buffered saline (PBS, pH 7.4), and homogenized in ice-cold PBS containing 0.01% butylated hydroxytoluene (BHT) to prevent oxidation. Homogenates were centrifuged at 10,000 × g for 10 min at 4 °C, and the resulting supernatants were collected and stored at − 80 °C until analysis. Tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interferon-gamma (IFN-γ) levels were quantified using commercially available ELISA kits (MyBioSource, USA), following the manufacturer’s instructions. Lipid peroxidation in liver and kidney tissues was assessed by measuring thiobarbituric acid reactive substances (TBARS), based on the reaction of thiobarbituric acid with malondialdehyde (MDA). Briefly, 100 mg of tissue was homogenized in 1 mL of ice-cold phosphate buffer (50 mM, pH 7.4) containing 0.01% butylated hydroxytoluene (BHT), then centrifuged at 10,000 × g for 10 min at 4 °C. The supernatant was mixed with 0.67% thiobarbituric acid and 10% trichloroacetic acid in 20% acetic acid, heated at 95 °C for 15 min, cooled, and then centrifuged. Absorbance was measured at 532 nm, and TBARS levels were measured using a 1,1,3,3-tetramethoxypropane (TEP) standard curve. Levels of superoxide dismutase (SOD; Cat. No. SD 2521), catalase (CAT; Cat. No. CA 2517), glutathione peroxidase (GPx; Cat. No. GP 2524), reduced glutathione (GSH; Cat. No. GR 2511), and total antioxidant capacity (TAC; Cat. No. TA 2518) were measured using commercial colorimetric kits (Biodiagnostic Co., Egypt) following the manufacturer’s instructions. For SOD, CAT, and GPx assays, tissue homogenates were prepared as described above. Enzyme activities were measured using commercial colorimetric kits (Biodiagnostic Co., Egypt) according to the manufacturer’s protocols. The results were normalized to total protein content in each sample, determined by the Bradford method, and expressed as units per milligram of protein (U/mg protein). Tissue levels of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interferon-gamma (IFN-γ) were quantified using commercially available ELISA kits (MyBioSource, USA), with all procedures carried out strictly according to the manufacturer’s protocols (TNF-α: Cat. No. MBS3805961; IL-1β: Cat. No. MBS2881170; IFN-γ: Cat. No. MBS9018347). The activity of cyclooxygenase-2 (COX-2) in hepatic and renal tissue was measured using a spectrophotometric assay [37]. Briefly, purified COX-2 (constituting 10% of the final reaction mixture) was pre-incubated with hematin (60 µM) and EDTA (3 µM) at 25 °C for 10 min before proceeding with the subsequent assay steps. Tetramethyl-p-phenylenediamine (TMPD) (3.3 mM) and arachidonic acid (200 µM) were added to the pre-incubated reaction mixture and incubated for an additional 10 min at 25 °C, after which TMPD oxidation was quantified by measuring absorbance at 590 nm. The rate of TMPD oxidation was calculated using its extinction coefficient (0.00826 µM⁻¹). COX-2 activity was expressed in units, where one unit corresponds to the amount of enzyme capable of oxidizing 1 nmol of TMPD at 25 °C. Histopathological analysis After euthanasia, liver and kidney tissues from each experimental group were immediately collected and fixed in 10% neutral-buffered formalin. Fixed tissues were then dehydrated through a graded ethanol series (70%, 80%, 90%, and 100%) for 1 h at each step. After dehydration, tissues were cleared in two consecutive baths of xylene (1 h each) and embedded in paraffin blocks. Five-micrometer sections were cut with a microtome, stained with Hematoxylin and Eosin (H&E), and evaluated under a light microscope, with images captured for documentation. Liver and kidney lesions were assessed in three mice, with three sections per slide. Each section was examined at 400× magnification over four fields, resulting in a total of 12 fields per organ. Histopathological lesions were scored on a standardized scale (0–3: none to severe; Tables 2 and 3). Average lesion scores per mouse were determined by averaging scores across all observed fields of liver and kidney sections. To ensure rigor and minimize bias, all slides were coded, and histopathological scoring was performed in a double-blind manner, such that both the examiner evaluating the slides and the investigator performing the data analysis were blinded to the treatment groups. The discrepancies of more than 10–15% (or one scoring unit on a 0–3 scale) were typically re-evaluated jointly to reach a consensus. Table 2A standardized semi-quantitative scale was employed to assess hepatic histopathological changes, allowing lesions to be graded from 0 (no alteration) to 3 (severe)ScoreComprehensive multiparametric system for liver evaluation.0 (none)No histopathological changes were detected.1 (mild)Liver sections showed occasional hepatocellular degeneration and necrosis, minimal inflammatory cell presence, and rare or absent vascular congestion.2 (moderate)Liver sections showed moderate vacuolar degeneration, scattered to multifocal hepatocellular necrosis, scattered inflammatory infiltration, and mild vascular congestion.3 (severe)Liver sections exhibited diffuse and severe hepatocellular degeneration with extensive necrosis, widespread inflammatory infiltration, and moderate to severe vascular congestion. A standardized semi-quantitative scale was employed to assess hepatic histopathological changes, allowing lesions to be graded from 0 (no alteration) to 3 (severe) Table 3Semi-quantitative assessment criteria for renal tissue pathologyScoreTubular degeneration and necrosisGlomerular changesInflammationHemorrhage0NoneNoneNoneNone1Histological examination revealed degenerative changes confined to 1–2 of the 12 examined areas.Histological analysis revealed glomerular atrophy in 1–2 of the 12 observed areas.Histological examination revealed inflammatory cells in 1–2 of the 12 observed areas.Histological examination revealed mild glomerular and interstitial congestion accompanied by rare hemorrhagic foci in 1–2 of the 12 evaluated fields.2Histological examination revealed degenerative changes with multifocal sloughing in 3–6 of the 12 microscopic fields.Histological examination revealed glomerular shrinkage in 3–4 of the 12 evaluated fields.Histological analysis revealed inflammation in 3–4 of the 12 evaluated fields.Histological analysis revealed minimal to mild interstitial congestion accompanied by hemorrhage in 3–4 of the 12 evaluated fields.3Histological examination revealed diffuse tubular necrosis in 7–9 of the 12 evaluated fields.Histological examination revealed lamellar fusion in 5–6 of the 12 evaluated fields.Histological examination revealed inflammation in 5–7 of the 12 evaluated fields.Histological examination revealed diffuse interstitial vascular congestion accompanied by hemorrhage in 5–6 of the 12 evaluated fields. Semi-quantitative assessment criteria for renal tissue pathology Statistical analysis The normality of the data and equality of variances were confirmed using the Shapiro–Wilk and Levene’s tests, respectively. For datasets that violated normality or homogeneity assumptions, appropriate non-parametric tests, such as the Kruskal–Wallis test followed by Dunn’s multiple comparison correction, were applied. Group differences were analyzed using one-way ANOVA (SAS, 2012; Proc ANOVA), and Tukey’s post hoc test was applied for multiple comparisons of parametric data, while Dunn’s correction was used for non-parametric data to control type I error. Survival outcomes were examined using the Kaplan–Meier method, and the log-rank (Mantel–Cox) test was used to compare survival curves. Median survival times, hazard ratios (HRs), and their corresponding 95% confidence intervals (CIs) were calculated to assess treatment effects. Results are expressed as mean ± standard error, with significance accepted at p < 0.05. Data visualization was carried out using GraphPad Prism 9.0, and multivariate analyses, including principal component analysis (PCA) and heatmap clustering, were generated using the SRplot online platform (https://www.bioinformatics.com.cn/en. Results Characterization of ASX-CNPs Transmission electron microscopy (TEM) analysis demonstrated that the ASX-CNPs possessed a well-defined spherical morphology with a narrow size distribution (Fig. 1A). The nanoparticles appeared uniformly dispersed without noticeable aggregation, and their diameters ranged between 12 and 20 nm, confirming successful nanoparticle formation at the nanoscale (Fig. 1B). The small particle size observed by TEM is advantageous for enhanced cellular uptake and biological performance. Dynamic light scattering (DLS) measurements further corroborated the nanoscale dimensions of the ASX-CNPs, revealing a hydrodynamic diameter of 13.8 nm and a polydispersity index (PDI) of 0.201 (Fig. 1C). The relatively low PDI indicates a moderately narrow size distribution and acceptable homogeneity of the nanoparticle population. The slightly larger hydrodynamic diameter compared to TEM measurements can be attributed to nanoparticle hydration and surface-associated polymer chains in the aqueous medium. The zeta potential analysis showed a highly positive surface charge (+ 33 mV) (Fig. 1D), reflecting the presence of protonated amino groups on the chitosan surface. This high positive zeta potential generates strong electrostatic repulsion between nanoparticles, thereby preventing aggregation and conferring excellent colloidal stability to the ASX-CNP dispersion. Encapsulation studies revealed a high drug-loading performance, with an encapsulation efficiency of 88.71% and a loading content of 15.26%. These results highlight the strong affinity between ASX and the chitosan–TPP matrix, likely driven by hydrophobic interactions and electrostatic forces, which facilitate efficient drug entrapment within the nanoparticle network. Characterization of astaxanthin-loaded chitosan nanoparticles (ASX-CNPs). Transmission electron microscopy (TEM) image A shows nearly spherical particles, and the size histogram B indicates that most particles are between 12 and 20 nm. Particle size distribution by volume C and zeta potential distribution D are also shown. Z-average size, polydispersity index (PDI), and zeta potential were 13.8 nm, 0.201, and + 33 mV, respectively Fourier-transform infrared (FTIR) spectroscopy further confirmed the successful incorporation of ASX into the chitosan nanoparticles. As shown in Fig. 2, the FTIR spectrum of ASX-CNPs exhibited notable peak shifts and band broadening compared to those of pure ASX and chitosan, indicating the formation of electrostatic interactions and hydrogen bonding among ASX, chitosan, and TPP. The disappearance or attenuation of characteristic ASX peaks suggests that ASX was molecularly dispersed within the polymeric matrix rather than physically adsorbed on the nanoparticle surface. FTIR spectra of pure astaxanthin (ASX), pure chitosan, pure tripolyphosphate (TPP), and ASX-loaded chitosan nanoparticles (ASX-CNPs). Characteristic peaks of ASX (~ 2920, 2850, and 1650 cm⁻¹) and chitosan (~ 3430, 1645, and 1550 cm⁻¹) are observed, while shifts and broadening in the ASX-CNP spectrum indicate successful encapsulation of ASX within the chitosan–TPP matrix through electrostatic and hydrogen-bonding interactions The in vitro release study demonstrated a distinct biphasic release profile for ASX from ASX-CNPs (Fig. 3). An initial burst release phase was observed within the first few hours, with approximately 22% of ASX released within 2 h. This initial release is likely attributed to the diffusion of ASX molecules weakly bound or located near the nanoparticle surface. Subsequently, a sustained and controlled release phase was observed, with cumulative ASX release reaching approximately 72% at 24 h and 88% at 48 h. The prolonged release behavior can be ascribed to the diffusion of ASX through the dense chitosan–TPP matrix, coupled with gradual polymer chain relaxation and partial erosion of the nanoparticle network. This controlled release profile underscores the potential of chitosan nanoparticles as an effective delivery system for ASX, capable of maintaining prolonged drug availability under physiological conditions. In vitro release profile of astaxanthin (ASX) from ASX-loaded chitosan nanoparticles (ASX-CNPs) in phosphate-buffered saline (PBS, pH 7.4) at 37 °C, showing an initial burst release followed by sustained and controlled drug release over 48 h Tumor growth and survival parameters Table 4 illustrates that the untreated EAC group exhibited the highest body weight gain due to tumor progression, whereas administration of both ASX formulations effectively attenuated this increase. Notably, ASX-CNPs produced a more substantial reduction in body weight than the crude ASX form (p < 0.05). Also, administration of either crude ASX or ASX-CNPs resulted in a significant reduction in ascitic fluid accumulation and viable tumor cell count in EAC-bearing mice, with the greatest effect observed in the nanoform-treated group (p < 0.05). Survival analysis further revealed marked differences in survival outcomes among the experimental groups. The log-rank test showed a statistically significant improvement in survival in both treated groups compared with untreated EAC-bearing mice (p < 0.05). The HR analysis indicated that treatment with crude ASX reduced the risk of death by approximately 76% (HR = 0.24), whereas ASX-CNPs further decreased the mortality risk by nearly 85% (HR = 0.15) relative to the EAC group. These findings confirm that both treatments effectively prolonged survival, with the nanoformulation demonstrating superior therapeutic efficacy (Fig. 4; Table 5). Table 4Effects of conventional and nanoformulated astaxanthin (ASX) on survival and tumor growth in EAC-Bearing MiceParametersEACEAC/ASXEAC/ ASX-CNPsp-valuesChange in body weight (%)42.25 ± 1.5231.92 ± 1.67#31.12 ± 2.87#0.0319Abdominal circumference (mm)11.75 ± 0.899.47 ± 0.586.14 ± 0.47#†0.0008EAC volume (mL)11.46 ± 0.328.14 ± 0.68#5.20 ± 0.55#†0.0001Viable EAC cell count (106/mL)56.55 ± 2.7244.30 ± 2.33#23.36 ± 3.42#†0.0001Treatment groups are: Control (saline), ASX (40 mg/kg), ASX-CNPs (40 mg/kg), EAC (0.2 mL EAC cells), EAC/ASX (ASX 40 mg/kg + EAC), and EAC/ASX-CNPs (ASX-CNPs 40 mg/kg + EAC). Values are presented as mean ± SE. # significantly different from the EAC group; † significantly different from the EAC/ASX group Effects of conventional and nanoformulated astaxanthin (ASX) on survival and tumor growth in EAC-Bearing Mice Treatment groups are: Control (saline), ASX (40 mg/kg), ASX-CNPs (40 mg/kg), EAC (0.2 mL EAC cells), EAC/ASX (ASX 40 mg/kg + EAC), and EAC/ASX-CNPs (ASX-CNPs 40 mg/kg + EAC). Values are presented as mean ± SE. # significantly different from the EAC group; † significantly different from the EAC/ASX group Kaplan–Meier survival curves showing the improved survival of Erlich Ascites Carcinoma (EAC)-bearing mice following treatment with astaxanthin (ASX) or astaxanthin-chitosan nanoparticles (ASX-CNPs) Table 5Survival analysis of Erlich Ascites Carcinoma (EAC)-bearing mice treated with astaxanthin (ASX) or astaxanthin-chitosan nanoparticles (ASX-CNPs) using Kaplan–Meier and log-rank (Mantel–Cox) testsGroupsMST (days)95% CIEvents (n)Censored (n)Log-rank vs. EAC (p-value)HR (vs. EAC)95% CI (HR)EAC11.5(7–16)510---1---EAC/ASX14(12–14)2130.0320.240.07–0.86EAC/ ASX-CNPs19(18–20)2130.0060.150.04–0.58MST mean survival time, HR hazard ratio, CI confidence interval. Treatment groups are: Control (saline), ASX (40 mg/kg), ASX-CNPs (40 mg/kg), EAC (0.2 mL EAC cells), EAC/ASX (ASX 40 mg/kg + EAC), and EAC/ASX-CNPs (ASX-CNPs 40 mg/kg + EAC) Survival analysis of Erlich Ascites Carcinoma (EAC)-bearing mice treated with astaxanthin (ASX) or astaxanthin-chitosan nanoparticles (ASX-CNPs) using Kaplan–Meier and log-rank (Mantel–Cox) tests MST mean survival time, HR hazard ratio, CI confidence interval. Treatment groups are: Control (saline), ASX (40 mg/kg), ASX-CNPs (40 mg/kg), EAC (0.2 mL EAC cells), EAC/ASX (ASX 40 mg/kg + EAC), and EAC/ASX-CNPs (ASX-CNPs 40 mg/kg + EAC) Apoptotic-related genes In this study, administration of either crude ASX or ASX-CNPs following EAC inoculation significantly upregulated the expression of pro-apoptotic genes caspase-3 (Fig. 5A) and Bax (Fig. 5B), while markedly downregulating the anti-apoptotic gene Bcl-2 (Fig. 5C) (p < 0.05). Notably, the nano-formulation (ASX-CNPs) exhibited superior efficacy compared to the crude form, demonstrating greater enhancement of Bax expression and a more pronounced suppression of Bcl-2 levels. Changes in apoptotic-related gene expression in Ehrlich Ascites Carcinoma (EAC)-bearing mice following treatment with astaxanthin (ASX) and astaxanthin-loaded chitosan Nanoparticles (ASX-CNPs). Treatment groups are: Control (saline), ASX (40 mg/kg), ASX-CNPs (40 mg/kg), EAC (0.2 mL EAC cells), EAC/ASX (ASX 40 mg/kg + EAC), and EAC/ASX-CNPs (ASX-CNPs 40 mg/kg + EAC). Values are presented as mean ± SE. # Significantly different from the EAC group; † Significantly different from the EAC/ASX group Kidney function Results presented in Table 6 demonstrated that serum levels of kidney function biomarkers, urea and creatinine, were significantly increased in EAC-bearing mice compared with all controls (p < 0.05), indicating marked renal impairment associated with tumor progression. Co-administration with either crude ASX or ASX-CNPs significantly reduced these elevated levels (p < 0.05). Notably, administration of the ASX-CNPs restored urea and creatinine levels to levels comparable to those of the negative control, with no significant differences (p > 0.05), indicating a pronounced nephroprotective effect. Regarding serum electrolytes, Na+ and Ca++ concentrations were significantly decreased, whereas K+ and Cl− levels were significantly increased following EAC induction (p < 0.05). However, co-treatment by ASX-CNPs significantly normalized these disturbances, resulting in no significant differences from the negative control for Na+, K+, and Ca++ (p > 0.05). These results indicate that ASX-CNPs exert a superior regulatory effect on renal function and electrolyte balance compared with the crude ASX. Table 6Effects of astaxanthin (ASX) and astaxanthin-loaded chitosan nanoparticles (ASX-CNPs) on kidney functions and electrolytes in Ehrlich Ascites Carcinoma (EAC)-Bearing MiceParametersControlASXASX-CNPsEACEAC/ASXEAC/ ASX-CNPsp-valuesCreatinine (mg/dL)0.64 ± 0.030.63 ± 0.060.62 ± 0.041.43 ± 0.16*1.08 ± 0.09*#0.81 ± 0.06*#†0.0075Urea (mg/dl)37.12 ± 2.6336.21 ± 3.2836.44 ± 2.6457.64 ± 4.11*46.22 ± 3.24*#41.18 ± 3.56*#0.0142Na+ (mmol/l)134.25 ± 3.13136.24 ± 4.11139.12 ± 3.27114.23 ± 2.20*125.12 ± 3.27#129.37 ± 4.03*0.0073K+ (mmol/l)3.22 ± 0.283.14 ± 0.363.12 ± 0.244.98 ± 0.31*4.62 ± 0.33*3.77 ± 0.20#0.0014Ca++ (mmol/l)1.37 ± 0.141.38 ± 0.111.39 ± 0.030.55 ± 0.02*0.84 ± 0.03*#1.14 ± 0.06#†0.0001Cl− (mmol/l)87.46 ± 3.1686.24 ± 3.6288.16 ± 3.93132.36 ± 4.15*123.64 ± 3.12*110.37 ± 4.44*#†0.0001Na+: Sodium; K+: Potassium; Ca++: Calcium; Cl−: Chloride; Treatment groups are: Control (saline), ASX (40 mg/kg), ASX-CNPs (40 mg/kg), EAC (0.2 mL EAC cells), EAC/ASX (ASX 40 mg/kg + EAC), and EAC/ASX-CNPs (ASX-CNPs 40 mg/kg + EAC).Values are presented as mean ± SE.* significantly different from the control group; # significantly different from the EAC group; † significantly different from the EAC/ASX group Effects of astaxanthin (ASX) and astaxanthin-loaded chitosan nanoparticles (ASX-CNPs) on kidney functions and electrolytes in Ehrlich Ascites Carcinoma (EAC)-Bearing Mice Na+: Sodium; K+: Potassium; Ca++: Calcium; Cl−: Chloride; Treatment groups are: Control (saline), ASX (40 mg/kg), ASX-CNPs (40 mg/kg), EAC (0.2 mL EAC cells), EAC/ASX (ASX 40 mg/kg + EAC), and EAC/ASX-CNPs (ASX-CNPs 40 mg/kg + EAC).Values are presented as mean ± SE.* significantly different from the control group; # significantly different from the EAC group; † significantly different from the EAC/ASX group Liver function Regarding liver function, total blood protein and its fractions (albumin and globulin) were significantly decreased in EAC-bearing mice compared with the control group (p < 0.05), indicating impaired hepatic synthetic capacity. Co-administration of either crude ASX or ASX-CNPs significantly increased these levels (p < 0.05), with the most pronounced improvement shown in the EAC/ASX-CNPs-treated group. Notably, no significant differences were detected between this group and the negative control for total protein and albumin (p > 0.05), suggesting effective restoration of hepatic protein synthesis. Regarding hepatic enzyme activities (AST, ALT, ALP, LDH, and GGT), all enzymes showed significant elevations in EAC-bearing mice compared with all control groups (p < 0.05), reflecting tumor-induced hepatic injury. Administration of the nanoform of ASX significantly attenuated these elevations, restoring ALT, ALP, and LDH activities to levels not significantly different from those of the negative control (p > 0.05). These results demonstrate the hepatoprotective potential of ASX-CNPs, which outperformed the crude form in preserving liver function and integrity (Table 7). Table 7Effects of astaxanthin (ASX) and astaxanthin-loaded chitosan nanoparticles (ASX-CNPs) on Liver functions in Erlich Ascites Carcinoma (EAC)-Bearing MiceParametersControlASXASX-CNPsEACEAC/ASXEAC/ ASX-CNPsp-valuesTP (g/dL)6.95 ± 0.457.13 ± 0.517.12 ± 0.384.10 ± 0.31*5.37 ± 0.38*#6.27 ± 0.40#0.0018Alb (g/dL)3.74 ± 0.133.89 ± 0.213.76 ± 0.142.16 ± 0.12*2.76 ± 0.09*#3.66 ± 0.15#†0.0163Glo (g/dL)3.21 ± 0.113.24 ± 0.233.36 ± 0.221.94 ± 0.06*2.61 ± 0.07*#2.61 ± 0.06*#0.0219ALT (U/L)38.16 ± 3.4637.16 ± 3.8637.46 ± 2.7374.15 ± 3.03*58.16 ± 4.13*#46.29 ± 3.16#†0.0008AST (U/L)61.12 ± 4.1758.13 ± 5.1557.14 ± 3.75124.16 ± 6.79*112.13 ± 4.84*93.13 ± 4.53*#†0.0001ALP (U/L)142.12 ± 8.10141.07 ± 6.26140.14 ± 6.84198.11 ± 7.98*181.26 ± 5.71*164.49 ± 8.63#0.0032LDH (U/L)274.13 ± 6.26271.24 ± 8.21279.61 ± 8.36366.29 ± 8.13*310.24 ± 6.46*#281.03 ± 6.29#†0.0009GGT (U/L)19.78 ± 2.1418.64 ± 2.4317.49 ± 1.8748.61 ± 3.13*31.15 ± 2.35*#28.43 ± 2.18*#0.0001TP total protein, Alb albumin, Glo globulin, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, LDH lactate dehydrogenase, GGT γ-glutamyl transferase. Treatment groups are: Control (saline), ASX (40 mg/kg), ASX-CNPs (40 mg/kg), EAC (0.2 mL EAC cells), EAC/ASX (ASX 40 mg/kg + EAC), and EAC/ASX-CNPs (ASX-CNPs 40 mg/kg + EAC). Values are presented as mean ± SE. * Significantly different from the control group; # Significantly different from the EAC group; † Significantly different from the EST/GSO group Effects of astaxanthin (ASX) and astaxanthin-loaded chitosan nanoparticles (ASX-CNPs) on Liver functions in Erlich Ascites Carcinoma (EAC)-Bearing Mice TP total protein, Alb albumin, Glo globulin, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, LDH lactate dehydrogenase, GGT γ-glutamyl transferase. Treatment groups are: Control (saline), ASX (40 mg/kg), ASX-CNPs (40 mg/kg), EAC (0.2 mL EAC cells), EAC/ASX (ASX 40 mg/kg + EAC), and EAC/ASX-CNPs (ASX-CNPs 40 mg/kg + EAC). Values are presented as mean ± SE. * Significantly different from the control group; # Significantly different from the EAC group; † Significantly different from the EST/GSO group Redox status In this study, TBARS levels in liver (Fig. 6A) and kidney (Fig. 7A) tissues were significantly elevated in EAC-bearing mice compared with all control groups (p < 0.05), indicating enhanced lipid peroxidation and oxidative stress. Co-treatment with both crude ASX and ASX-CNPs markedly reduced TBARS levels, with the EAC/ASX-CNPs-treated group showing the most pronounced reduction (p < 0.05). Regarding antioxidant status, the levels of reduced GSH and the activities of antioxidant enzymes, including GPx, CAT, and SOD, as well as TAC in liver (Fig. 6B–F) and kidney tissues (Fig. 7B–F), were significantly decreased following EAC induction compared with all control groups (p < 0.05). However, treatment with ASX-CNPs significantly enhanced these antioxidant parameters, surpassing the crude form in elevating GPx and TAC in liver tissue and reduced GSH in kidney tissue (p < 0.05). These findings indicate that ASX-CNPs exert superior antioxidant efficacy, effectively counteracting tumor-induced oxidative stress and restoring redox balance. Changes in hepatic redox balance in Ehrlich Ascites Carcinoma (EAC)–Bearing Mice following treatment with astaxanthin (ASX) and astaxanthin-loaded chitosan nanoparticles (ASX-CNPs). TBARS: thiobarbituric acid reactive substances; GSH: reduced glutathione; GPx: glutathione peroxidase; CAT: catalase; SOD: superoxide dismutase; TAC: total antioxidant capacity. Treatment groups are: Control (saline), ASX (40 mg/kg), ASX-CNPs (40 mg/kg), EAC (0.2 mL EAC cells), EAC/ASX (ASX 40 mg/kg + EAC), and EAC/ASX-CNPs (ASX-CNPs 40 mg/kg + EAC). * Significantly different from the control group; # Significantly different from the EAC group; † Significantly different from the EAC/ASX group Changes in renal redox balance in Ehrlich Ascites Carcinoma (EAC)–Bearing Mice following treatment with astaxanthin (ASX) and astaxanthin-loaded chitosan nanoparticles (ASX-CNPs). TBARS: thiobarbituric acid reactive substances; GSH: reduced glutathione; GPx: glutathione peroxidase; CAT: catalase; SOD: superoxide dismutase; TAC: total antioxidant capacity. ASX: astaxanthin (40 mg/kg body weight); ASX-CNPs: astaxanthin-loaded chitosan nanoparticles (40 mg/kg body weight); EAC: inoculated with EAC cells (0.2 mL); EAC/ASX: astaxanthin (40 mg/kg body weight) + EAC cells (0.2 mL); EAC/ASX-CNPs: astaxanthin-loaded chitosan nanoparticles (40 mg/kg body weight) + EAC cells (0.2 mL). Values are presented as mean ± SE. * Significantly different from the control group; # Significantly different from the EAC group; † Significantly different from the EAC/ASX group Inflammation response In this study, the levels of proinflammatory cytokines, including TNF-α, IFN-γ, and IL-1β (Figs. 8A–C), as well as COX-2 activity in hepatic and renal tissues (Figs. 9A and B), were significantly elevated in EAC-bearing mice compared with all control groups (p < 0.05), indicating pronounced inflammatory responses associated with tumor progression. Co-treatment with ASX-CNPs markedly reduced these inflammatory mediators, showing greater efficacy than the crude ASX form, particularly in suppressing TNF-α, IFN-γ, and COX-2 activity in hepatic tissue (p < 0.05). Notably, no significant differences were observed between the negative control and EAC/ASX-CNPs-treated groups for IFN-γ in hepatic tissue and both IFN-γ and IL-1β in renal tissue (p > 0.05), confirming the potent anti-inflammatory potential of the ASX-CNPs. Changes in hepatic inflammatory cytokines in Ehrlich Ascites Carcinoma (EAC)–Bearing Mice following treatment with astaxanthin (ASX) and astaxanthin-loaded chitosan nanoparticles (ASX-CNPs). TNF-α: tumor necrosis factor-alpha; IFN-γ: interferon-gamma; IL-1β: interleukin-1 beta. ASX: astaxanthin (40 mg/kg body weight); ASX-CNPs: astaxanthin-loaded chitosan (40 mg/kg body weight); EAC: inoculated with EAC cells (0.2 mL); EAC/ASX: astaxanthin (40 mg/kg body weight) + EAC cells (0.2 mL); EAC/ASX-CNPs: astaxanthin-loaded chitosan nanoparticles (40 mg/kg body weight) + EAC cells (0.2 mL). Values are presented as mean ± SE. * Significantly different from the control group; # Significantly different from the EAC group; † Significantly different from the EAC/ASX group Changes in cyclooxygenase-2 (COX-2) activity in hepatic and renal tissues in Ehrlich Ascites Carcinoma (EAC)–Bearing Mice following treatment with astaxanthin (ASX) and astaxanthin-loaded chitosan nanoparticles (ASX-CNPs). ASX: astaxanthin (40 mg/kg body weight); ASX-CNPs: astaxanthin-loaded chitosan (40 mg/kg body weight); EAC: inoculated with EAC cells (0.2 mL); EAC/ASX: astaxanthin (40 mg/kg body weight) + EAC cells (0.2 mL); EAC/ASX-CNPs: astaxanthin-loaded chitosan nanoparticles (40 mg/kg body weight) + EAC cells (0.2 mL). Values are presented as mean ± SE. * Significantly different from the control group; # Significantly different from the EAC group; † Significantly different from the EAC/ASX group Histopathological results Figure 10A–F depicts the histological architecture of liver tissues from EAC-bearing mice treated with either crude ASX or ASX-CNPs. The hepatocytes in the normal control, ASX, and ASX-CNPs groups maintained normal structural integrity without any evident cellular degeneration or inflammatory infiltration. Normal hepatic structure was evident, including central veins, intact lobules, and well-preserved hepatocytes, which exhibited their typical polygonal or hexagonal shape with intensely eosinophilic cytoplasm and centrally positioned nuclei (Figs. 10A–C). Conversely, liver sections from EAC-bearing mice showed severe histopathological lesions, including central vein congestion, diffuse vacuolar degeneration, and nuclear necrosis (Fig. 10D). Meanwhile, the hepatic tissue of EAC-bearing mice treated with ASX or its nanoparticle formulation exhibited near-normal histological appearance, including radiating hepatocyte cords around the central veins and well-organized hepatic lobules (Figs. 10E and F). Regarding the hepatic severity score, it increased significantly in the EAC group relative to the control and non-tumor-treated groups (ASX and ASX-CNPs). Co-treatment with either ASX or ASX-CNPs following EAC induction resulted in a marked improvement, with the most pronounced reduction in severity recorded in the EAC/ASX-CNPs group (Fig. 11). Representative liver photomicrographs (400×, scale bar = 50 μm) from control and experimental groups: A control (0.2 mL saline, orally); B ASX (40 mg/kg/day, orally); C ASX-CNPs (40 mg/kg/day, orally); D EAC (2.5 × 10⁶ cells, intraperitoneally, + 0.2 mL saline orally); E EAC + ASX (20-day oral ASX treatment post-inoculation); F EAC + ASX-CNPs. Key features: central vein (CV), hepatocytes (H), sinusoids (S), cytoplasmic vacuolation (V) Representative liver photomicrographs of Ehrlich Ascites Carcinoma (EAC)–bearing mice following treatment with astaxanthin (ASX, 40 mg/kg) and astaxanthin-loaded chitosan nanoparticles (ASX-CNPs, 40 mg/kg). Experimental groups: EAC (0.2 mL cell suspension); EAC/ASX: astaxanthin (40 mg/kg body weight) + EAC cells (0.2 mL); EAC/ASX-CNPs: astaxanthin-loaded chitosan nanoparticles (40 mg/kg body weight) + EAC cells (0.2 mL). Values are mean ± SE. *Significantly different from control; # significantly different from EAC; † significantly different from EAC/ASX Renal tissues from the control, ASX, and ASX-CNPs-treated mice displayed normal histological appearance, showing preserved Bowman’s capsules, intact glomeruli, and well-organized proximal and distal convoluted tubules (Fig. 12A–C). Conversely, the renal tissues of EAC-bearing mice showed distinct histopathological alterations, including marked vascular congestion, periglomerular lymphocytic infiltration, and atrophic or shrunken glomeruli (Fig. 12D). Renal tissues from the EAC/ASX and EAC/ASX-CNPs groups appeared largely normal, displaying intact tubules and glomeruli, with minimal congestion of renal vasculature (Figs. 12E and F). The EAC group exhibited a significant increase in renal severity score compared with the control and both ASX- and ASX-CNPs-treated groups. Treatment with ASX or ASX-CNPs significantly improved the histopathological profile, with the greatest improvement observed in the EAC/ASX-CNPs-treated group (Fig. 13). Representative kidney photomicrographs (400×, scale bar = 50 μm) from control and experimental groups: A control (0.2 mL saline, orally); B ASX (40 mg/kg/day, orally); C ASX-CNPs (40 mg/kg/day, orally); D EAC (2.5 × 10⁶ cells, intraperitoneally, + 0.2 mL saline orally); E EAC + ASX (20-day oral ASX treatment post-inoculation); F EAC + ASX-CNPs. Key structures: glomeruli G, tubules T Representative kidney photomicrographs of Ehrlich Ascites Carcinoma (EAC)–bearing mice following treatment with Astaxanthin (ASX, 40 mg/kg) and Astaxanthin-Loaded Chitosan Nanoparticles (ASX-CNPs, 40 mg/kg). Experimental groups: EAC (0.2 mL cell suspension), EAC/ASX (ASX + EAC), and EAC/ASX-CNPs (ASX-CNPs + EAC). Values are mean ± SE. *Significantly different from control; # significantly different from EAC; † significantly different from EAC/ASX Multivariable analyses Principal Component Analysis (PCA) was employed to evaluate multivariate biochemical and molecular differences among experimental groups. Figure 14A (PC1 = 90.76%, PC2 = 7.25%) illustrates that the six groups (Control, ASX, ASX-CNPs, EAC, EAC + ASX, and EAC + ASX-CNPs) are predominantly distinct from one another, with PC1 serving as the primary factor for group-specific clustering. Figure 14B (PC1 = 86.9%, PC2 = 6.9%) illustrates a distinct difference between Control and EAC, attributable to the biochemical alterations associated with tumor growth. Figure 14C (PC1 = 65.9%, PC2 = 27.8%) illustrates that EAC + ASX and EAC + ASX-CNPs are diverging from EAC, while the ASX-CNPs group approaches the Control cluster. This indicates a more complete restoration of metabolic balance. Figure 14D (PC1 = 54.9%, PC2 = 40.3%) indicates that the EAC + ASX group is approaching normality. Figures 14E (PC1 = 76%, PC2 = 22.4%) and 15 F (PC1 = 85.8%, PC2 = 8.8%) present a comparison between ASX and ASX-CNPs. Nanoencapsulation significantly alters the metabolic profile, enhancing the stability and efficacy of the compound in vivo. PCA indicates that ASX-CNPs are more effective in restoring biochemical and molecular parameters disrupted by EAC compared to free ASX. Principal Component Analysis (PCA) plots illustrating group-wise separation based on key biochemical and molecular variables, including antioxidant enzymes (SOD, CAT, GPx), oxidative stress markers (TBARS, GSH, TAC), pro- and anti-apoptotic proteins (Bax, Bcl-2, Caspase-3), and inflammatory cytokines (TNF-α, IL-1β, IFN-γ). A Overall distribution of all experimental groups (Control, ASX, ASX-CNPs, EAC, EAC + ASX, and EAC + ASX-CNPs; PC1 = 90.76%, PC2 = 7.25%), showing global treatment effects. B Clear separation between Control and EAC (PC1 = 86.9%, PC2 = 6.9%), reflecting tumor-induced alterations in biochemical and molecular profiles. C EAC + ASX and EAC + ASX-CNPs are separated from EAC, with the nanoformulation group shifting closer to the Control cluster, indicating superior normalization of molecular parameters (PC1 = 65.9%, PC2 = 27.8%). D Distinct clustering of ASX versus ASX-CNPs (PC1 = 76%, PC2 = 22.4%), demonstrating the effect of nanoencapsulation. E Partial normalization of EAC + ASX compared to EAC (PC1 = 54.9%, PC2 = 40.3%), highlighting moderate recovery with free ASX. F Divergence between ASX and ASX-CNPs (PC1 = 85.8%, PC2 = 8.8%) confirms enhanced metabolic modulation induced by nanoparticle delivery. Group separations in all panels reflect combined effects of antioxidant, apoptotic, and inflammatory variables, with closer clustering toward Control indicating more effective restoration of normal biochemical and molecular status Discussion EAC is a well-established murine tumor model that replicates several features of fast-growing cancers with high metabolic activities [38]. Hence, the Ehrlich ascites carcinoma (EAC) model was intentionally used because it is a well-established and widely accepted experimental model for evaluating antitumor activity, oxidative stress, inflammation, apoptosis, and therapeutic responses to nanoparticle-based formulations. Additionally, the model allows reliable assessment of tumor burden, survival, and systemic biochemical alterations [39, 40]. Among natural antioxidants, ASX is distinguished by its powerful free radical–scavenging effects and its pro-apoptotic action on tumor cells [41, 42]. Despite these benefits, its therapeutic application is constrained by suboptimal bioavailability and poor solubility [43]. The use of CNPs as carriers for ASX significantly enhances its bioavailability, solubility, and tumor-targeting capacity, resulting in improved therapeutic efficacy and protection against tumor-associated toxicity [28, 29, 44, 45]. In this study, we assessed the antitumor potential of ASX-CNPs in EAC-bearing mice, with particular emphasis on their protective effects against tumor-associated hepatic and renal toxicity. ASX-CNPs administration resulted in a significant decrease in body weight gain compared with EAC-bearing mice, reflecting a reduction in the tumor’s impact on overall health. In addition, an increase in survival among tumor-bearing individuals is recognized as a hallmark of meaningful anticancer efficacy [33]. Inoculation with EAC resulted in a significant increase in ascitic tumor volume and viable tumor cell numbers, accompanied by a decline in non-viable cell counts. Administration of ASX-CNPs significantly diminished tumor volume and viable cell counts and increased the numbers of non-viable cells, consistent with earlier studies demonstrating the antitumor effects of ASX in ascitic tumors [33, 46]. Molecular analyses revealed a significant elevation of caspase-3 activity in both free ASX and ASX-CNPs treated mice compared to EAC treated mice, with the greatest effect observed in the EAC/ASX-CNP treated group. Moreover, ASX-CNP administration downregulated the anti-apoptotic gene BCL-2 and upregulated the pro-apoptotic gene Bax, indicating potent induction of apoptosis. These findings align with earlier reports suggesting that ASX modulates caspases, BCL-2, and Bax, thereby promoting apoptosis in various carcinoma models [47–49]. Another study further showed that ASX boosts the apoptotic activity of doxorubicin in tumor-bearing mice by inducing cell cycle arrest at the G₂/M phase and activating p53, which in turn triggers caspase activation and apoptosis [33]. Also, ASX was demonstrated to induces apoptosis via p53-dependent regulation of Bax and BCL-2, corroborating our results that ASX-CNPs potentiate pro-apoptotic pathways in tumor cells Similarly [20], . The elevated serum levels of ALT, AST, LDH, ALP, and GGT in EAC-bearing mice suggest liver injury due to tumor cell accumulation. The resultant hepatocellular damage may increase membrane permeability, allowing the release of intracellular enzymes into the bloodstream. Oxidative stress and excessive ROS generation underlie this pathological state, which triggers lipid peroxidation, elevates plasma Ca²⁺ levels, impairs mitochondrial Ca²⁺ transport and storage, and ultimately induces hepatocyte apoptosis and necrosis [50, 51]. Administration of ASX-CNPs significantly reduced these elevated enzyme levels, demonstrating their hepatoprotective effect. This protective effect is likely mediated by ASX’s antioxidant activity, which may preserve membrane integrity and reduce oxidative damage [52]. The recovery of total protein and its fractions further indicates that ASX-CNPs protect hepatic synthetic function, possibly by alleviating tumor-induced injury and preventing oxidative protein modifications. These findings also support ASX’s immunomodulatory properties [53], suggesting that it contributes to both cytoprotection and immune regulation. Beyond hepatotoxicity, EAC-bearing mice showed significant renal dysfunction, reflected by increased serum urea, creatinine, chloride, potassium, and disturbances in sodium and calcium levels. Such alterations reflect kidney injury caused by tumor growth and are consistent with previous studies [54, 55]. The observed renal impairment is likely driven by ROS-mediated disruption of cellular homeostasis, causing functional and structural kidney damage. Additionally, tumor-induced hypoxia may elevate VEGF expression through HIF-1α activation, stimulating aberrant angiogenesis and further impairing renal structure [56, 57]. In this study, ASX-CHNPs administration significantly ameliorated renal dysfunction and electrolyte disturbances in EAC-bearing mice. These biochemical benefits were corroborated by histopathological analyses, which revealed intact basement membranes and well-preserved glomerular and tubular architecture, despite ongoing metabolic and hemodynamic challenges. These observations are consistent with reports indicating that ASX may exert renal protection through antioxidant and anti-apoptotic mechanisms [58, 59]. Herein, tumor-bearing mice exhibited a significant elevation in hepatic and renal TBARS levels, accompanied by a significant reduction in the activities of key antioxidant enzymes (CAT, SOD, and GPx), compared with control animals. Administration of ASX-CNPs effectively reversed these oxidative alterations more efficiently than crude ASX, highlighting the improved antioxidant potential conferred by the nanoparticle formulation. This was further confirmed by a pronounced elevation of TAC in EAC/ASX-CNP–treated group compared with those receiving crude ASX, relative to EAC-bearing mice. In the same context, hepatic and renal GSH levels were significantly lower in EAC-bearing mice than in normal controls. This depletion may be attributed to ROS overproduction, which drives GSH oxidation to GSSG as part of the cellular antioxidant response [60]. The current data showed that administration of ASX, particularly as nanoparticles, restored hepatic and renal GSH levels, consistent with its robust antioxidant and free-radical-scavenging effects. According to the prior studies outcomes, The notable renoprotective effects of ASX are likely mediated by its ability to inhibit NF-κB-driven inflammatory signaling and activate Nrf2-dependent antioxidant responses, thereby promoting cellular resilience and reducing fibrosis [59]. Moreover, comparable nephroprotective effects have been noted in rats with experimentally induced renovascular occlusion, supporting ASX’s widespread cytoprotective potential [61]. In addition, Concurrently, EAC-induced oxidative stress was shown in the previous studies to trigger monocyte - and macrophage-mediated inflammation, evidenced by increased TNF-α, IL-1β, and IFN-γ in hepatic and renal tissues via activation of NF-кB pathway with enhanced release of the proinflammatory cytokines [62, 63]. ASX-CNP administration significantly decreased cytokine levels, likely through its strong antioxidant activity and suppression of nitric oxide synthesis [64]. Overall, the present results indicate that ASX-CNPs alleviate hepatic and renal dysfunction in EAC-bearing mice through a combination of antioxidant and anti-inflammatory mechanisms. Previous studies have demonstrated that ASX effectively protects liver and kidney tissues by reducing ROS and malondialdehyde levels, while simultaneously enhancing key antioxidant enzymes, including SOD, CAT, and GPx. ASX also inhibits key oxidative and inflammatory signaling pathways, including NF-κB and Wnt/β-catenin, thereby alleviating oxidative stress and improving both hepatic and renal function in hepatocellular and renal carcinoma experimental models [15, 46, 65–67]. Our findings revealed that both crude ASX and ASX-CNPs significantly inhibited COX-2 activity in hepatic and renal tissues of EAC-bearing mice, thereby attenuating EAC-induced inflammatory responses. The present results align with previous scientific reports indicating that ASX exerts potent anti-inflammatory properties through suppression of pro-inflammatory cytokines, inhibition of NF-κB activation, and downregulation of inflammatory mediators such as COX-2 and inducible nitric oxide synthase (iNOS), ultimately protecting tissues from inflammation-induced damage [68–70]. Notably, the nanoparticle formulation exhibited superior efficacy, indicating that ASX-CNPs may offer a more potent therapeutic approach for alleviating tumor-induced oxidative stress and inflammation, underscoring the novelty and translational relevance of this work. Study limitations A key limitation of the present study is the absence of in vivo pharmacokinetic evaluation to confirm the enhanced bioavailability of ASX delivered via chitosan nanoparticles. Although in vitro release demonstrated sustained drug release and the physicochemical properties of ASX-CNPs suggest improved absorption, these findings cannot fully predict in vivo ADME behavior, requiring further pharmacokinetic and biodistribution studies for validation. Additionally, only a single dose was evaluated, which precludes assessment of dose–response relationships and limits determination of the optimal therapeutic range, highlighting the need for future studies incorporating multiple dosing regimens. Study design has its own limitations, which do not significantly affect the study outcomes. An important limitation is the absence of a blank chitosan nanoparticle-treated group, which precludes definitive attribution of observed effects solely to astaxanthin loading and limits full assessment of carrier-related biological activity and safety. Another limitation is the absence of a dedicated vehicle control group to rule out any potential influence of the formulation solvent on the observed biological outcomes, although the solvent system used is generally considered biologically inert at the administered dose. Also, the initiation of treatment immediately after tumor inoculation, which reflects a preventive/early intervention model rather than a true therapeutic setting; therefore, future studies should employ delayed treatment protocols to better evaluate efficacy against established tumors. Furthermore, the current work exclusively used the Ehrlich ascites carcinoma model, which, although well-established for preliminary anticancer evaluation, does not fully recapitulate the tumor microenvironment of solid tumors; therefore, future studies should incorporate solid tumor models to enhance translational relevance. Additionally, the expression of apoptotic markers (caspase-3, Bax, and Bcl-2) was assessed only at the mRNA level using qRT-PCR, without confirmation at the protein level through Western blotting or immunohistochemical analyses, which may limit the mechanistic interpretation of the molecular findings. Other Limitations include lack of long-term toxicity assessment, and absence of comparison with standard chemotherapeutic agents. Overall, these limitations underscore the necessity for further in vivo pharmacokinetic, biodistribution, dose–response, multi-model, and safety studies to fully evaluate the translational potential of ASX-CNPs as a clinical anticancer treatment. Conclusion The present study demonstrates that ASX-CNPs possess superior therapeutic efficacy compared with free ASX in EAC-bearing mice. ASX-CNPs effectively suppressed tumor growth, enhanced survival, and conferred marked hepatic and renal protection by modulating apoptotic, oxidative stress, and inflammatory pathways. Histopathological evaluation revealed substantial improvement in liver and kidney architecture, confirming the protective efficacy of ASX-CNPs. The improved bioavailability, stability, and sustained release of ASX in its nanoparticle form further enhanced its biological activity. These findings highlight the promising potential of ASX-CNPs as a novel nanotherapeutic strategy for cancer treatment and organ protection. Acknowledgments Declaration of generative AI and AI-assisted technologies The authors declare that no artificial intelligence (AI) or AI-assisted technologies were used in the conduct of this study. Authors’ contributions M.S.A. and E.M.E. conceived and designed the study. E.M.E. performed the experimental work, data acquisition, and primary data analysis. H.A.A., A.B.A., and A.A.M. contributed to biochemical and histopathological analyses. M.S.F. participated in molecular investigations and statistical interpretation of results. A.N.A. assisted in nanoparticle preparation and characterization. M.M.E. contributed to manuscript drafting, data visualization, and critical revision for intellectual content. All authors discussed the results, reviewed the manuscript, and approved the final version for publication. Funding The authors extend their appreciation to Northern Border University, Saudi Arabia, for supporting this work through project number (NBU-FFR-2026-2510-04). Data availability The data supporting the findings of this study are available from the corresponding author upon reasonable request. No publicly archived datasets are applicable. Declarations Ethics approval and consent to participate Ethical approval for all procedures was obtained from Mansoura University Animal Care and Use Committee (VM.R.25.12.259). The study adhered to Directive 2010/63/EU and was conducted in accordance with the ARRIVE guidelines 2.0, ensuring the protection of animals used for scientific purposes. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Ekramy M. Elmorsy, Email: Ekramy.elmorsy@nbu.edu.sa Mona M. Elghareeb, Email: monael_ghareeb@mans.edu.eg References Associated Data Data Availability Statement The data supporting the findings of this study are available from the corresponding author upon reasonable request. No publicly archived datasets are applicable.